Mesoblast Receives $5.05m for Stem Cell Pipeline Development
Filed with ASX ·
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
Earlier from Mesoblast
- Key US Patent Granted For Treatment Of Rheumatoid Arthritis
- GVHD Product Launched In Japan
- Increased Survival Using MSB Cells In Children With aGVHD
- Half Yearly Report and Accounts (including Appendix 4D)
- MSB Therapy Shows Benefit In First Cohort Of RA Patients
Later from Mesoblast
- Key European Patent Granted for Mesoblasts MPCs
- Mesoblast Acquires Osiris Cultured Stem Cell Business
- Mesoblast, Intrexon and Ziopharm to Target Cancers
- Mesoblast provides update on clinical programs of prochymal
- Mesoblast Reports Positive Type 2 Diabetes Trial Results
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast